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Introduction: A population-based survey conducted in Brazilian capital cities found that only
16%  of the population had ever been tested for hepatitis C. These data suggest that much  of
the Brazilian population with HCV infection remains undiagnosed. The distribution of age
ranges at diagnosis and its association with the degree of hepatitis C are still unknown in
Brazilian  patients.
Material  and methods: Patients with HCV infection, diagnosed by HCV RNA (Amplicor-HCV,
Roche),  were included in the study. Patients with HBV or HIV coinfection, autoimmune
diseases,  or alcohol intake > 20 g/day were excluded. HCV genotyping was performed by
sequence  analysis, and viral load by quantitative RT-PCR (Amplicor, Roche). The METAVIR
classiﬁcation  was used to assess structural liver injury. The Chi-square (2) test and student’s
t-test  were used for between-group comparisons. Spearman’s rank correlation coefﬁcient
were  used for analysing the correlation between parameters.
Results: A total of 525 charts were reviewed. Of the patients included, 49.5% were male, only
10%  of the patients were aged less than 30 years; peak prevalence of HCV infection occurred
in  the 51-to-60 years age range. Genotype 1 accounted for 65.4% of the cases. Information
on  HCV subtype was  obtained in 227 patients; 105 had subtype 1a and 122 had 1b. According
to  the degree of structural liver injury, 8.3% had F0, 23.4% F1, 19.8% F2, 11.9% F3, and 36.5%
F4.  Age at diagnosis of hepatitis correlated signiﬁcantly with ﬁbrosis (rs = 0.307, p < 0.001).
The  degree of ﬁbrosis increased with advancing age. Only age at diagnosis and fasting blood
glucose  were independently associated with disease stage. Those patients with subtype 1a
had higher prevalence of F2–F4 than those with subtype 1b.
Conclusion:  In Brazil, diagnosis of hepatitis C is more commonly established in older patients(age 45–60 years) with more advanced disease. Reassessment of strategies for hepatitis C
try idiagnosis  in the coun∗ Corresponding author at: Department of Medicine, Universidade Fede
P, Brazil.
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Fig. 1 – Distribution of age at hepatitis diagnosis by patient508  b r a z j i n f e c t d 
Introduction
According to ofﬁcial estimates of the prevalence of hepatitis
C  in Brazil and demographic data from the Brazilian Insti-
tute  of Geography and Statistics (IBGE),1,2 approximately 2.5
million  people in the country would have been positive for
anti-hepatitis C virus (anti-HCV) antibodies. A population-
based survey conducted in major state capitals found that
only  16% of the population had ever been tested for HCV.3
Just over 60,000 patients with hepatitis C have received antivi-
ral  treatment in the country over the last 6 years.4 These
data  show that a large portion of the Brazilian population
infected with HCV remains undiagnosed. The high preva-
lence  of advanced hepatitis C in the country appears to reﬂect
the  lack of an aggressive policy for diagnosing this serious
condition, which is compounded by its oligosymptomatic
course. Hepatitis C is the second leading cause of cirrhosis
in  Brazil and the leading cause of hepatocellular carcinoma,
and,  consequently, the most common cause of liver trans-
plantation in the country.5–7 However, no consistent data are
available  on the association between age range at diagnosis
and  disease progression. Therefore, the present study sought
to  assess the demographic proﬁle of patients with conﬁrmed
HCV  infection presenting for their ﬁrst visit at a tertiary refer-
ral  center, and ascertain whether correlations exist between
this  variable and clinical and histological severity of the
illness.
Material  and  methods
We  reviewed the charts of all adults (age > 15 years) seen
consecutively between January 2009 and June 2013 at the out-
patient  Gastroenterology Clinic of Universidade Federal de
São  Paulo (UNIFESP), a tertiary referral service for patients
with  HCV-related liver disease. The inclusion criterion was  a
conﬁrmed HCV infection. After diagnosis of HCV exposure,
usually by detection of anti-HCV antibodies by second-
generation and, later in the study period, third-generation
enzyme-linked immunosorbent assay (ELISA) (Abbott IMX,
Abbott  Laboratories, USA), diagnosis was  conﬁrmed by detec-
tion  of HCV RNA in peripheral blood through the polymerase
chain  reaction (PCR) (Amplicor-HCV, Roche Diagnostics). HCV
genotyping  was  later carried out by sequence analysis of the
5′ noncoding region, and viral load was  measured by quanti-
tative  RT-PCR (Amplicor, Roche).
For analysis of the association between age at diagnosis
and  degree of liver injury, gender distribution, and distribu-
tion  of viral genotypes, we excluded patients with hepatitis
B  virus or HIV coinfection, autoimmune diseases, or alcohol
intake  > 20 g/day (regardless of gender). All patients had under-
gone  percutaneous liver biopsy, except those with clinical
manifestations or ultrasound and/or endoscopy ﬁndings con-
sistent  with cirrhosis. The resulting biopsy specimens were
embedded  in parafﬁn and stained with hematoxylin/eosin
(H&E), reticulin, and Masson’s trichrome for histological exam-
ination.  On histopathological analysis, structural liver injury
was  assessed and graded in accordance with the histological
METAVIR classiﬁcation.8age  range.
Statistical analysis: Results were expressed as means and
standard  deviations. The Chi-square (2) test or student’s t-
test was  used for between-group comparisons as appropriate.
Spearman’s rank was  used to test for correlation between
parameters. The signiﬁcance level was set at 5% (p < 0.05).
Results
Initial assessment included the charts of 525 patients with
HCV  infection, of whom 49.5% were  male and 50.5% were
female.  Only 10% of these patients were aged < 30 years at diag-
nosis;  peak prevalence occurred between the ages of 51 and 60
years  (Fig. 1).
In  61 patients with conﬁrmed viral infection, liver injury
could  not be staged due to their refusal to undergo biopsy, loss
to  follow-up, or the presence of exclusion criteria not identi-
ﬁed  at the time of enrollment. The remaining 464 patients had
a  gender distribution similar to that of the initial sample and
a  mean age of 48.9 ± 12.4 years (range, 15–78 years). Regarding
genotype, 65.4% had genotype 1 HCV, 29% had genotype 3, 7%
had genotype 2, and 4% had other genotypes. Furthermore,
HCV subtype was  determined in 227 patients with genotype 1:
105 had subtype 1a and 122 had subtype 1b. Regarding the dis-
tribution  of degrees of structural liver injury, 8.3% of patients
had  no ﬁbrosis (F0), 23.4% were  graded as F1, 19.8% as F2, 11.9%
as  F3, and 36.5% as cirrhotic (F4).
Age at diagnosis of hepatitis correlated signiﬁcantly with
the  degree of structural liver injury (rs = 0.307, p < 0.001). As
shown  in Fig. 2, degree of ﬁbrosis increased with advancing
age.  The percentage of patients with cirrhosis also increased
progressively with increasing age range at diagnosis; con-
versely,  the percentage of patients with mild or no ﬁbrosis
decreased progressively with advancing age. The presence of
advanced  ﬁbrosis did not correlate with gender, body mass
index,  genotype, viral load, or epidemiology of infection.
The  gender distribution was  reversed among patients diag-
nosed  after age 45 years. Among patients younger than this
cutoff,  men  accounted for 60% of all diagnosed cases, whereas
after  this age, women were the majority, accounting for 55%
of  cases on average (Fig. 3). However, there were  no signiﬁcant
gender  differences in the degree of ﬁbrosis (2 = 2.221, p = 0.695)
or  the distribution of viral genotypes (2 = 1.185, p = 0.757) in
this  age range.
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Fig. 2 – Distribution of degree of structural liver injury by
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There were  no signiﬁcant differences in gender, age, body
ass  index, or the presence of diabetes mellitus among differ-
nt  genotype 1 HCV subtypes. However, when patients were
tratiﬁed  by disease stage, despite no differences in the pres-
nce  of advanced ﬁbrosis (F3, F4), patients with subtype 1a had
 statistically higher prevalence of substantial ﬁbrosis (F2–F4)
han  patients with subtype 1b. A history of blood transfusion
as  more  prevalent among patients with subtype 1b (Table 1).
iscussionlthough restricted to the adult population, these data show
hat  diagnosis of hepatitis C in Brazil increases in prevalence
Table 1 – Clinical, demographic, and histological features of pat
subtype.
Genotype 1a (n = 105) 
Age (SD) 45.9 (11.4) 
Females (%) 50.5% 
BMI > 25 59% 
Disease stage
F0–F2  vs. F3–F4 49% vs. 51% 
F0–F1 vs. F2–F4 25% vs. 75% 
History of transfusion (%) 31.4% 
Diabetes mellitus 14% 4;1 8(5):507–511  509
from the fourth decade of life and that nearly half of all
patients  in whom the condition is detected are diagnosed
between the ages of 46 and 60 years, with peak prevalence
at  age 50–60 years. These data essentially reproduce those
reported by Foccacia et al., 9 who conducted a seroepidemio-
logic population-based survey of anti-HCV antibody positivity
in  the city of São Paulo and found that the most signiﬁcant
prevalence was found after age 30 years, with peak preva-
lence  at 50–60 years. These ﬁndings were  also consistent with
the  distribution of cases reported to the Brazilian Ministry
of  Health Notiﬁable Diseases Information System (Sistema de
Informac¸ão  de Agravos de Notiﬁcac¸ão, Sinan).10
Another remarkable ﬁnding of this study was  the impact of
age  at diagnosis on the degree of liver injury, with a growing
prevalence of advanced ﬁbrosis and a progressive reduction
in  the number of mild cases with advancing age. On analy-
sis  of factors associated with disease progression, only age
and  the presence of diabetes mellitus correlated with more
advanced  disease in our sample. The importance of age in the
natural  history of chronic hepatitis C has been demonstrated
in  a variety of studies conducted in Brazil and elsewhere.
Patients infected at an older age or those with a longer dis-
ease  course present with more  advanced stages.11–14 Several
investigations have demonstrated rapid disease progression
among  patients infected at older ages, particularly in studies
of  patients enrolled with early-stage ﬁbrosis (F0, F1), where
progression to advanced ﬁbrosis was  more  common among
patients  older than 40–50 years.15,16
The most signiﬁcant conclusion one can draw from the
data  presented herein is that, in addition to diagnosing
only a minute portion of those persons who  are actually
infected with HCV in Brazil, the majority of these patients
are  being diagnosed at advanced stages of hepatitis C. The
lack  of early diagnosis of hepatitis C (i.e., during the asymp-
tomatic  stage) hinders its curative treatment and has a
major  impact on health expenditures. Indeed, the costs of
treating  the complications of cirrhosis and performing liver
transplantation far exceed those of therapy aimed at erad-
icating  the virus. Several studies have demonstrated the
cost-effectiveness of broader programs  for HCV detection and
diagnosis  based on patient age rather than testing of high-risk
groups  alone.17,18 These studies led the U.S. Centers for Dis-of  the established HCV risk groups to include the so-called
“baby  boomer” generation, i.e., persons born in the years
1945–1965.19
ients with hepatitis C genotype 1, stratiﬁed by HCV
Genotype 1b (n = 122) p
48.7 (13.1) 0.092
50.8% 0.92
65% 0.466
57% vs. 43% 0.321
44% vs. 56% 0.007
47.5% 0.002
18% 0.562
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On the other hand, the ﬁnding that patients are being
diagnosed at more  advanced stages of the disease is a
cause  for concern, as these patients are known to respond
relatively poorly to antiviral therapy, whether with inter-
feron  alfa/pegylated interferon and ribavirin or with protease
inhibitor-based triple therapy; furthermore, these patients
experience more  adverse effects during treatment.20–23
In the present study, we were  unable to identify any
changes in the mode of disease transmission over time. Blood
transfusion  was  the leading known potential source of dis-
ease  transmission, followed by intravenous drug use. Blood
transfusion  had occurred, on average, 32.4 ± 9.7 years before
diagnosis  (median, 33 years). This probably explains the age
difference  in gender distribution. There was  an increase in
the  prevalence of women  being diagnosed with HCV as age
advanced,  but gender was  not signiﬁcantly associated with the
degree  of ﬁbrosis. The best explanation for this ﬁnding appears
to  be slower progression of liver disease in women,14,24 which
is  corroborated by the prolonged clinical course seen in these
patients.  Indeed, most of these patients still had blood trans-
fusion  as the most important factor for disease transmission.
Another interesting ﬁnding in this study was  provided by
HCV  subtype analysis. Some investigations have suggested
that  subtype 1b would be associated with more  marked dis-
ease  progression and a greater trend toward development of
hepatocellular  carcinoma than subtype 1a.25–27 Other authors,
however, maintain that these negative ﬁndings are only asso-
ciated  with the more  advanced age of patients with subtype
1b,  who  are believed to be phylogenetically older than those
with  subtype 1a.25–27 Although patients with subtype 1b in our
case  series had a greater mean age and were more  likely to
have  contracted HCV through blood transfusion (which rein-
forces  the notion of phylogenetic precedence), we  found no
signiﬁcant  differences in the degree of ﬁbrosis when patients
were  stratiﬁed using advanced ﬁbrosis (grade F3/F4) as a cut-
off.  Conversely, when grade F2 (substantial ﬁbrosis) was  used
as  the cutoff for patient stratiﬁcation, we  found a greater fre-
quency  of substantial ﬁbrosis among patients with subtype 1a
than among those with subtype 1b. There were  no signiﬁcant
differences in gender, age, body mass index or the presence
of  diabetes among the subtypes, which suggests that higher-
grade  ﬁbrosis was  exclusively attributable to HCV subtype.
As  this was  a retrospective study and subtype analysis was
limited  to patients with genotype 1 HCV, we cannot conﬁrm
these  ﬁndings. However, a more  in-depth investigation of the
relationship  between genotype 1 subtypes and progression of
hepatitis  C in Brazilian patients is certainly warranted.
This study clearly shows that methods for diagnosing hep-
atitis  C infection must improve in Brazil. If we  continue to
diagnose  patients after the age of 50 years, we will be select-
ing  for cases that are more  likely to develop complications,
less likely to respond to antiviral therapy, and more  likely to
develop  cirrhosis and hepatocellular carcinoma and require
liver  transplantation.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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